ReviewDrugs2005
Second-generation antihistamines: actions and efficacy in the management of allergic disorders.
Review in Drugs, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 106 citations in OpenAlex.
- Trial
- Variability of histamine pharmacodynamic response in children with allergic rhinitis.Journal of clinical pharmacology · 2013Trial
- Antipruritic Placebo Effects by Conditioning H1-antihistamine.Psychosomatic medicineTrial
- AAAAI physician survey: Current antihistamine use in the clinical setting.The journal of allergy and clinical immunology. Global · 2026Article
- Spectral residual augmented classical least squares for simultaneous green determination of cetirizine, fexofenadine and loratadine by UV spectrophotometry in pharmaceuticals and environmental samples.Scientific reports · 2026Article
- Management and Immunotherapy for Fungal Allergy: Clinical Practice and Unmet Needs.Clinical reviews in allergy & immunology · 2026Review
- Advance in Managing Indoor Cat Allergen Proteins: Molecular Insights, Detection, and Control.International journal of molecular sciences · 2025Review
- Article
- Flight safety risk assessment of self-medication among fighter pilots: a cross-sectional study.International journal of clinical pharmacy · 2023Article
- Pollen respiratory allergy: Is it really seasonal?The World Allergy Organization journal · 2023Review
- Comparative Study of Chemical Stability of Two HJournal of analytical methods in chemistry · 2019Article
- Combining MucilAir™ and VitrocellPharmaceutics · 2018Article
- Effects of inclusion of cetirizine hydrochloride in β-cyclodextrin.Journal of inclusion phenomena and macrocyclic chemistry · 2018Article
- Polypharmacy leads to increased prevalence of potentially inappropriate medication in the Indonesian geriatric population visiting primary care facilities.Therapeutics and clinical risk management · 2018Article
- Determination of Some Non-sedating Antihistamines via Their Native Fluorescence and Derivation of Some Quantitative Fluorescence Intensity - Structure Relationships.Journal of fluorescence · 2015Article
- Respiratory allergies: a general overview of remedies, delivery systems, and the need to progress.ISRN allergy · 2014Review
- Improvement of effect of water-in-oil microemulsion as an oral delivery system for fexofenadine: in vitro and in vivo studies.International journal of nanomedicine · 2011Article
- H1 antihistamines: current status and future directions.The World Allergy Organization journal · 2008Article
- Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.Clinical pharmacokinetics · 2008Review
- Drug-induced urinary retention: incidence, management and prevention.Drug safety · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antihistamines are useful medications for the treatment of a variety of allergic disorders. Second-generation antihistamines avidly and selectively bind to peripheral histamine H1 receptors and, consequently, provide gratifying relief of histamine-mediated symptoms in a majority of atopic patients. This tight receptor specificity additionally leads to few effects on other neuronal or hormonal systems, with the result that adverse effects associated with these medications, with the exception of noticeable sedation in about 10% of cetirizine-treated patients, resemble those of placebo overall. Similarly, serious adverse drug reactions and interactions are uncommon with these medicines. Therapeutic interchange to one of the available second-generation antihistamines is a reasonable approach to limiting an institutional formulary, and adoption of such a policy has proven capable of creating substantial cost savings. Differences in overall efficacy and safety between available second-generation antihistamines, when administered in equivalent dosages, are not large. However, among the antihistamines presently available, fexofenadine may offer the best overall balance of effectiveness and safety, and this agent is an appropriate selection for initial or switch therapy for most patients with mild or moderate allergic symptoms. Cetirizine is the most potent antihistamine available and has been subjected to more clinical study than any other. This agent is appropriate for patients proven unresponsive to other antihistamines and for those with the most severe symptoms who might benefit from antihistamine treatment of the highest potency that can be dose-titrated up to maximal intensity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.